• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The ENHANCE trial: Simvastatin and ezetimibe in familial hypercholesterolemia [Classics Series]

byLauren KoandAndrew Cheung, MD MBA
September 11, 2014
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with familial hypercholesterolemia, simvastatin and ezetimibe combination therapy does not result in significant differences in carotid artery thickness when compared to treatment with simvastatin alone.

2. Treatment with simvastatin and ezetimibe led to significantly greater reductions in LDL cholesterol, triglyceride, and C-reactive protein levels as compared to treatment with simvastatin alone.

3. There were no significant differences between the two groups in the rates of adverse events or drug discontinuation.

Original Date of Publication: April 3, 2008

Study Rundown: Ezetimibe is a cholesterol-absorption inhibitor that lowers plasma cholesterol by decreasing the amount of cholesterol absorption in the small intestine. This drug is sometimes used in combination with statins, and this combination has been shown to further reduce levels of low-density lipoprotein (LDL) when compared to statins alone. No prior large-scale randomized clinical trial had been conducted to assess the effect of adding ezetimibe to statins on atherosclerosis progression. In the ENHANCE trial, 720 patients with familial hypercholesterolemia were randomized to receive simvastatin with placebo or simvastatin with ezetimibe. After 24 months of therapy, there was no significant difference between the two groups in mean change in intima-media thickness of the carotid arteries (P=0.29). Nevertheless, patients that took combination therapy rather than simvastatin alone experienced greater reductions in LDL cholesterol, triglyceride, and C-reactive protein levels.

Click to read the study in NEJM

RELATED REPORTS

#VisualAbstract: Simvastatin and Rifaximin Does Not Improve Outcomes in Decompensated Cirrhosis

Simvastatin does not improve outcomes in patients critically ill with COVID-19

#VisualAbstract: Simvastatin is non-superior to control in critically ill COVID-19 patients

In-Depth [randomized controlled trial]: This double-blinded randomized control trial was originally published in the NEJM in 2008. It was conducted at 18 centres in the United States, Canada, South Africa, Spain, Denmark, Norway, Sweden, and the Netherlands. Patients were eligible for the study if they were between 30-75 years of age and had been diagnosed with familial hypercholesterolemia by genotyping or World Health Organization diagnostic criteria. Exclusion criteria included having high-grade stenosis/occlusion of the carotid artery, a history of carotid endarterectomy/stenting, homozygous familial hypercholesterolemia, New York Heart Association class III or IV congestive heart failure, and cardiac arrhythmia. All patients underwent a screening phase, a single-blind 6-week placebo run-in period, and a double-blind study period lasting 24 months. The primary outcome was the mean change in intima-media thickness of the carotid arteries, as measured by ultrasonography of the carotid arteries.

A total of 720 patients with familial hypercholesteremia were randomized into two treatment groups: 1) simvastatin 80 mg daily with placebo or 2) simvastatin 80 mg daily and ezetimibe 10 mg daily. In the simvastain-only group, the mean change in thickness was 0.0058±0.0037 mm, while it was 0.0111±0.0038 mm in the simvastatin-ezetimibe group, an insignificant difference (P=0.29). Patients in the simvastatin-ezetimibe group experienced a 16.5% greater reduction in LDL levels compared with the simvastatin-only group (P<0.01). Patients in the combination group also experienced significantly greater reductions in triglyceride and C-reactive protein levels, when compared with simvastatin alone (P<0.01). There were no significant differences between the two groups in the rates of adverse events and medication discontinuation.

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: ezetimibe (Zetia)simvastatin
Previous Post

Hemorrhage during gastrectomy linked to increased cancer recurrence

Next Post

Benzodiazepine use linked with Alzheimer’s disease

RelatedReports

#VisualAbstract: Simvastatin and Rifaximin Does Not Improve Outcomes in Decompensated Cirrhosis
StudyGraphics

#VisualAbstract: Simvastatin and Rifaximin Does Not Improve Outcomes in Decompensated Cirrhosis

February 19, 2025
Palliative chemotherapy associated with more ICU treatment at end-of-life
Emergency

Simvastatin does not improve outcomes in patients critically ill with COVID-19

February 12, 2024
#VisualAbstract: Simvastatin is non-superior to control in critically ill COVID-19 patients
StudyGraphics

#VisualAbstract: Simvastatin is non-superior to control in critically ill COVID-19 patients

January 12, 2024
Gender conformity influences use of laxatives and muscle-building products
Cardiology

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

September 20, 2022
Next Post
Dementia prevalence declining in the UK

Benzodiazepine use linked with Alzheimer's disease

Ultrasound, flow reserve guided coronary interventions provide minimal benefit

Coronary angioplasty safe and effective at facilities without on-site cardiothoracic surgery

Preterm birth associated with elevated plasma insulin levels

GLP-1 agonist and basal insulin an effective anti-diabetic regimen

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke
  • Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery
  • 2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.